A psychometric study found AMSTAR 2 to be a valid and moderately reliable appraisal tool.


Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
10 2019
Historique:
received: 20 12 2018
revised: 15 04 2019
accepted: 24 05 2019
pubmed: 4 6 2019
medline: 22 5 2020
entrez: 2 6 2019
Statut: ppublish

Résumé

The objectives of this study were to determine the interrater reliability (IRR) of assessment of multiple systematic reviews (AMSTAR) 2 for reviews of pharmacological or psychological interventions for the treatment of major depression, to compare it to that of AMSTAR and risk of bias in systematic reviews (ROBIS), and to assess the convergent validity between the appraisal tools. Two groups of four raters were each assigned one of two samples of 30 systematic reviews. All eight raters applied AMSTAR 2 to their sample. Each group also applied either AMSTAR or ROBIS. Fleiss' kappa and Gwet's AC The median kappa values as a measure of IRR indicated a moderate agreement for AMSTAR 2 (median = 0.51), a substantial agreement for AMSTAR (median = 0.62), and a fair agreement for ROBIS (median = 0.27). Validity results showed a positive association for AMSTAR and AMSTAR 2 (r = 0.91) as well as ROBIS and AMSTAR 2 (r = 0.84). For the overall rating, AMSTAR 2 showed a high concordance with ROBIS and a lower concordance with AMSTAR. The IRR of AMSTAR 2 was found to be slightly lower than the IRR of AMSTAR and higher than the IRR of ROBIS. Validity measurements indicate that AMSTAR 2 is closely related to both ROBIS and AMSTAR.

Identifiants

pubmed: 31152864
pii: S0895-4356(18)31099-0
doi: 10.1016/j.jclinepi.2019.05.028
pii:
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

133-140

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Robert C Lorenz (RC)

Federal Joint Committee (Healthcare), Medical Consultancy Department, Gutenbergstr. 13, 10587 Berlin, Germany; Division of Social and Preventive Medicine, University of Potsdam, Research Focus Cognitive Sciences, Am Neuen Palais 10, Potsdam 14469, Germany. Electronic address: robert.lorenz@g-ba.de.

Katja Matthias (K)

Federal Joint Committee (Healthcare), Medical Consultancy Department, Gutenbergstr. 13, 10587 Berlin, Germany.

Dawid Pieper (D)

Witten/Herdecke University, School of Medicine, Faculty of Health, Evidence-based Health Services Research, IFOM - Institute for Research in Operative Medicine, Ostmerheimer Str. 200, 51109 Cologne, Germany.

Uta Wegewitz (U)

Federal Institute for Occupational Safety and Health, Nöldnerstr.40-42, 10317 Berlin, Germany.

Johannes Morche (J)

Federal Joint Committee (Healthcare), Medical Consultancy Department, Gutenbergstr. 13, 10587 Berlin, Germany.

Marc Nocon (M)

Federal Joint Committee (Healthcare), Medical Consultancy Department, Gutenbergstr. 13, 10587 Berlin, Germany.

Olesja Rissling (O)

Federal Joint Committee (Healthcare), Medical Consultancy Department, Gutenbergstr. 13, 10587 Berlin, Germany.

Jacqueline Schirm (J)

Federal Joint Committee (Healthcare), Medical Consultancy Department, Gutenbergstr. 13, 10587 Berlin, Germany.

Anja Jacobs (A)

Federal Joint Committee (Healthcare), Medical Consultancy Department, Gutenbergstr. 13, 10587 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH